Watch our on-demand webinar.
On Thursday, July 18, at noon ET, EditCo Bio hosted a webinar, “AI-driven identification and validation of novel synthetic lethal gene pairs” with Evariste and Arctoris' Ulysses®. Fill out the form to get access to the on-demand recording now.
What You'll Learn
Learn how the team at Evariste is using AI to accelerate drug discovery with the help of two powerful automated platforms: CRISPR editing through EditCo's Express Cell Pools and cell health validation through Arctoris' Ulysses.®
- Synthetic lethality (SL) is a highly promising therapeutic strategy in oncology, but the toolbox of existing actionable SL gene pairs remains limited.
- Using an AI-driven pipeline, Evariste has identified novel SL gene pairs and validated them through a combination of high-throughput CRISPR editing and robotically enabled cell biology assays.
- Further validation was performed for a novel SL pair where the druggable gene is the known oncology target FAK, demonstrating that this pipeline robustly identifies clinically actionable targets with well-defined patient populations.
About the Speaker:
Dr. Daniel Miller is a principal scientist at Evariste, an AI-enabled biotech with a discovery platform covering all of the preclinical stages of drug discovery. He studied for his PhD in cell signaling and cancer biology at the Francis Crick Institute before moving to the Institute of Cancer Research for postdoctoral research, validating novel molecular glue-like degraders in B-cell lymphoma. At Evariste, he has established a target identification platform focussed on identifying new synthetic lethal gene pairs and manages the biological assays that support Evariste’s drug discovery pipeline.
